|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.45/1.06
|
企业价值
5.86B
|
资产负债 |
每股账面净值
1.60
|
现金流量 |
现金流量率
--
|
损益表 |
收益
396.59M
|
每股收益
2.25
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/07 04:13 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |